Skye Bioscience (SKYE)
(Delayed Data from NSDQ)
$3.88 USD
-0.23 (-5.60%)
Updated Sep 29, 2025 04:00 PM ET
After-Market: $3.86 -0.02 (-0.52%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SKYE 3.88 -0.23(-5.60%)
Will SKYE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SKYE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SKYE
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
SKYE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SKYE
Crossed Above 20 Day Moving Average appears for SKYE after 14.17% move
Hammer Candlestick appears for SKYE after 0.56% move
12 Health Care Stocks Moving In Friday's After-Market Session
50 Day Moving Average Resistance appears for SKYE after 2.98% move
SKYE Fell Below 20 Day Moving Average on September 23